DDInter1423 DDInter1376
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pentobarbital {u} (Compound) resembles {v} (Compound) Thiopental
Pentobarbital {u} (Compound) binds {v} (Gene) GABRA5
Pentobarbital {u} (Compound) upregulates {v} (Gene) BUB1B
Pentobarbital {u} (Compound) downregulates {v} (Gene) GSTZ1
Pentobarbital {u} (Compound) causes {v} (Side Effect) Dizziness
Pentobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Pentobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Pentobarbital {u} may lead to a major life threatening interaction when taken with {v} Morphine
Pentobarbital (Compound) resembles Thiopental (Compound)
Pentobarbital (Compound) binds GABRA5 (Gene)
Pentobarbital (Compound) upregulates BUB1B (Gene)
Pentobarbital (Compound) downregulates GSTZ1 (Gene)
Pentobarbital (Compound) causes Dizziness (Side Effect)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Pentobarbital may lead to a major life threatening interaction when taken with Morphine